HAO

Haoxi Health Technology Limited (HAO) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

No five-year revenue, EPS, or FCF CAGR is provided, so there is no evidence of repeatable compounding versus peers.

TTM ROIC is deeply negative at -43.0%, indicating current capital deployment is destroying value rather than funding scalable revenue expansion.

R&D intensity is only 0.17% of revenue, suggesting limited reinvestment capacity for product, platform, or market expansion relative to better-funded peers.

Very low capex-to-revenue implies a light asset base, but without proven growth conversion it has not translated into durable scaling versus peers.

Market Tailwinds

Score:

No segment or market-share data is provided, so there is no evidence of demand capture or share gains supporting long-term growth versus peers.

The available metrics show weak operating economics, which usually limits the ability to convert any market tailwind into sustained revenue growth.

Negative EV-to-sales and negative FCF yield indicate the market is pricing in impaired fundamentals, not a visible multi-year expansion path.

Without disclosed end-market exposure or backlog evidence, peer-relative growth visibility remains materially weaker than for companies with proven demand momentum.

Scalability Expansion

Score:

Capex intensity is extremely low, which can support scalability, but the absence of positive returns means expansion capacity is not yet proven.

Net debt to EBITDA of 4.25x constrains reinvestment flexibility and makes scaling more dependent on balance-sheet repair than growth funding.

Interest coverage is deeply negative, so financing capacity is weaker than peers and may restrict expansion before revenue can compound.

The current structure appears asset-light, but weak profitability prevents that structure from translating into scalable long-term revenue growth.

Constraints Limitations

Score:

Negative ROIC is the dominant structural constraint because it signals that incremental capital is not creating durable growth capacity.

High leverage and negative interest coverage materially limit reinvestment optionality versus peers with stronger balance sheets and self-funded growth.

Missing historical growth metrics prevent evidence of sustained compounding, which lowers confidence in long-term scalability relative to peers.

The combination of weak returns and constrained financing suggests structural impairment to growth, not merely temporary execution volatility.

Overall Score

Score:

HAO shows limited 10-year growth potential because current capital deployment is value-destructive, leverage is elevated, and there is no disclosed evidence of sustained revenue compounding versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Haoxi Health Technology Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →